Choose Your Country or Region

Cemiplimab (anti-PD-1)

Synonyms: REGN-2810, cemiplimab-rwlc

Catalog No.A2022 Purity:99.3%

Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.

Click to purchase the isotype control of Cemiplimab (anti-PD-1)

Selleck's Cemiplimab (anti-PD-1) has been cited by 1 publication

Purity & Quality Control

Batch: Purity: 99.3% Protein concentration: 5 mg/ml Endotoxin Level: <1 EU/mg

99.3

Choose Selective PD-1/PD-L1 Inhibitors

Name	Citation	PD-1/PD-L1 interaction	PD-1	PD-1/PD-L1
GS-4224	0	++++
INCB086550	0	++		++
BMS-1001	0	+		+
BMS-1166	5	+++
PD-1/PD-L1 Inhibitor 3	12	+++
BMS-1	11	++
BMS202	20	+
CA-170 (AUPM-170)			✔
SR 0987		✔		IL17,RORγt
Spartalizumab (anti-PD-1)		✔
Camrelizumab (anti-PD-1)		✔
AUNP-12			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.
Features	Human IgG4

In Vitro
In vitro	In cell-based assays, REGN2810 reverses PD-1-dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells.^[1]
Cell Research:	Objective: T cell activation bioassays Cells: Jurkat/AP-1-Luc/hPD-1 cells, HEK293/hCD20 cells, HEK293/hCD20/hPD-L1 cells Concentrations: 0.1 pM-0.1 μM Incubation Time: 4-6 h Method: Antigenpresenting cell (APC)-like HEK293 cells are generated by lentiviral transduction of human CD20 and human PD-L1. T-cell receptor (TCR) activation is achieved by an antiCD3 x anti-CD20 bispecific antibody. To generate a dose response curve for anti-CD3 x anti-CD20, the bispecific molecule is serially diluted and tested with 50,000/well Jurkat/AP-1-Luc/hPD-1 and 10,000/well HEK293/hCD20 or HEK293/hCD20/hPD-L1 cells in a 96-well plate. Serially diluted REGN2810 is tested under similar conditions in the presence of a fixed concentration of anti-CD3 x anti-CD20 (100 pM). Plates are incubated at 37°C for 4-6 hours. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/ Objective: T cell activation bioassays Cells: HEK293/hCD20/hPD-L1 cells, CD4+ T cells, HEK293/hCD20/hPD-L1 cells Concentrations: 0.1 pM-0.1 μM Incubation Time: 72 h Method: HEK293/hCD20/hPD-L1 cells are treated with 50 mg/mL mitomycin C for 30 minutes at 37°C to inhibit proliferation. Serially diluted REGN2810 is incubated with 50,000/well preactivated CD4+ T cells and 25,000/well of HEK293/hCD20/hPD-L1 cells in the presence of 2 nM anti-CD3 x anti-CD20 bispecific antibody in a 96-well plate for 72 hours. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/ Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

In Vitro

In vitro

In cell-based assays, REGN2810 reverses PD-1-dependent attenuation of T-cell receptor signaling in engineered T cells and enhances responses of human primary T cells.^[1]

Cell Research:

Objective: T cell activation bioassays
Cells: Jurkat/AP-1-Luc/hPD-1 cells, HEK293/hCD20 cells, HEK293/hCD20/hPD-L1 cells
Concentrations: 0.1 pM-0.1 μM
Incubation Time: 4-6 h
Method: Antigenpresenting cell (APC)-like HEK293 cells are generated by lentiviral transduction of human CD20 and human PD-L1. T-cell receptor (TCR) activation is achieved by an antiCD3 x anti-CD20 bispecific antibody. To generate a dose response curve for anti-CD3 x anti-CD20, the bispecific molecule is serially diluted and tested with 50,000/well Jurkat/AP-1-Luc/hPD-1 and 10,000/well HEK293/hCD20 or HEK293/hCD20/hPD-L1 cells in a 96-well plate. Serially diluted REGN2810 is tested under similar conditions in the presence of a fixed concentration of anti-CD3 x anti-CD20 (100 pM). Plates are incubated at 37°C for 4-6 hours.
Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

Objective: T cell activation bioassays
Cells: HEK293/hCD20/hPD-L1 cells, CD4+ T cells, HEK293/hCD20/hPD-L1 cells
Concentrations: 0.1 pM-0.1 μM
Incubation Time: 72 h
Method: HEK293/hCD20/hPD-L1 cells are treated with 50 mg/mL mitomycin C for 30 minutes at 37°C to inhibit proliferation. Serially diluted REGN2810 is incubated with 50,000/well preactivated CD4+ T cells and 25,000/well of HEK293/hCD20/hPD-L1 cells in the presence of 2 nM anti-CD3 x anti-CD20 bispecific antibody in a 96-well plate for 72 hours.
Reference: https://pubmed.ncbi.nlm.nih.gov/28265006/

Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

In Vivo
In vivo	Cemiplimab (REGN2810) binds the humanized PD-1 receptor and inhibits growth of MC38 murine tumors in human PD-1 knock-in mice. As REGN2810 binds to cynomolgus monkey PD-1 with high affinity, pharmacokinetic and toxicologic assessment of REGN2810 is performed in cynomolgus monkeys. High doses of REGN2810 are well tolerated, without adverse immune-related effects.^[1]
Animal Research	Objective: MC38 mouse colon carcinoma Animal Models: adult human PD-1 knock-in mice Formulation: -- Dosages: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006 Objective: pharmacokinetic (PK) study Animal Models: cynomolgus monkeys (Macaca fascicularis) Formulation: -- Dosages: 1 mg/kg, 5 mg/kg, 15 mg/kg Administration: i.v. Reference: https://pubmed.ncbi.nlm.nih.gov/28265006 Cemiplimab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

References
[1] Elena Burova, et al. Mol Cancer Ther. 2017 May;16(5):861-870.

References

[1] Elena Burova, et al. Mol Cancer Ther. 2017 May;16(5):861-870.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1801342-60-8
Isotype	Human IgG4
Source	HEK293
Formulation	PBS buffer. Contains no stabilizers or preservatives
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.